BLI Banque de Luxembourg Investments Trims Stake in Masimo Corporation $MASI

BLI Banque de Luxembourg Investments decreased its position in Masimo Corporation (NASDAQ:MASI) by 28.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 48,839 shares of the medical equipment provider’s stock after selling 19,661 shares during the period. BLI Banque de Luxembourg Investments’ holdings in Masimo were worth $6,400,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of MASI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Masimo by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after purchasing an additional 66 shares in the last quarter. Clearstead Advisors LLC increased its stake in shares of Masimo by 18.4% in the 3rd quarter. Clearstead Advisors LLC now owns 470 shares of the medical equipment provider’s stock valued at $69,000 after purchasing an additional 73 shares in the last quarter. Hantz Financial Services Inc. increased its stake in shares of Masimo by 12.9% in the 4th quarter. Hantz Financial Services Inc. now owns 655 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 75 shares in the last quarter. Assetmark Inc. increased its stake in shares of Masimo by 5.5% in the 4th quarter. Assetmark Inc. now owns 1,850 shares of the medical equipment provider’s stock valued at $241,000 after purchasing an additional 97 shares in the last quarter. Finally, Orion Porfolio Solutions LLC increased its stake in shares of Masimo by 2.2% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 4,871 shares of the medical equipment provider’s stock valued at $819,000 after purchasing an additional 104 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MASI shares. Wolfe Research lowered Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a report on Wednesday, February 18th. Stifel Nicolaus set a $180.00 target price on Masimo in a report on Tuesday, February 17th. Raymond James Financial cut Masimo from an “outperform” rating to a “market perform” rating in a report on Friday, March 27th. Finally, Weiss Ratings raised Masimo from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Nine investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Masimo presently has a consensus rating of “Hold” and an average target price of $180.40.

Masimo Price Performance

MASI stock opened at $179.94 on Tuesday. The firm has a market capitalization of $9.42 billion, a PE ratio of -17.07, a price-to-earnings-growth ratio of 1.81 and a beta of 1.11. Masimo Corporation has a 1 year low of $125.94 and a 1 year high of $179.97. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.68 and a quick ratio of 1.45. The business has a 50 day simple moving average of $178.51 and a 200-day simple moving average of $159.66.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.